Conditional survival in patients treated with vascular endothelial growth factor-targeted therapy for advanced renal cell carcinoma
Conditional survival in patients treated with vascular endothelial growth factor-targeted therapy for advanced renal cell carcinoma
复制标题
血管内皮生长因子靶向治疗晚期肾细胞癌患者的条件生存
DOI：
10.1007/s00432-012-1266-3
复制
发表时间：
2012-06
影响因子：
3.6
通讯作者：
Dai, B.
中科院分区：
文献类型：
--
作者：
Ye, D. W.;Hong, Y. P.;Zhang, H. L.;Shi, G. H.;Xiao, W. J.;Wang, Z. H.;Yao, X. D.;Zhang, S. L.;Dai, B.
目的：当患者存活一段时间后，二次生存（CS）为患者提供更相关的预后信息。本研究的目的是确定接受血管内皮生长因子靶向治疗的晚期肾细胞癌（RCC）患者的CS。方法对2006 ~ 2011年收治的符合纳入标准的345例患者进行回顾性分析。从治疗到第24个月，计算幸存者的1年条件生存率和实际生存率。调整协变量影响后，产生亚组特定的CS率。采用Cox比例风险模型评估基线和1年里程碑的预后因素。结果存活至6个月、12个月、18个月、24个月的患者多活1年的概率分别为72.2%、76.3、78.2、78.6%。根据恒风险组，最初被划分为中危或低危的患者CS显著增加。对于治疗后存活24个月的患者，无论最初的风险归因如何，次年的调整后CS均超过80%。与基线分析相比，恒风险组在存活1年后的生存率较低。在多因子模型中加入疾病控制状态，可显著提高1年生存率（p< 0.01）。结论：scs为接受靶向治疗的晚期RCC幸存者的预期寿命提供了有用的信息。此外，特定时期内的疾病控制状况对预测后续生存至关重要。
PurposeConditional survival (CS) offers more relevant prognostic information for patients once they have survived for some time. The objective of this study was to determine the CS for advanced renal cell carcinoma (RCC) patients treated with vascular endothelial growth factor-targeted therapy.MethodsA total of 345 patients treated between 2006 and 2011 fulfilled the inclusion criteria and were reviewed for analyses. The 1-year conditional and actual survival rates were calculated for survivors from treatment to month 24. Subgroup-specific CS rates were generated after adjustment of the covariate influence. The Cox proportional hazard models were used to assess the prognostic factors at baseline and 1-year landmark.ResultsThe probabilities of surviving an additional year given survival to 6, 12, 18, and 24 months were 72.2, 76.3, 78.2, and 78.6 %, respectively. Remarkable increase in CS was observed in patients initially classified as intermediate or poor risk according to Heng risk groups. For patients survived 24 months after treatment, the adjusted CS for the following year was over 80 % regardless of initial risk attribution. Compared to baseline analysis, Heng risk groups were less predictive of survivorship after surviving 1 year. The addition of disease control status to multifactorial model significantly improved survival estimation for 1-year survivors (p< 0.01).ConclusionsCS provides useful information regarding life expectancy for survivors of advanced RCC treated with targeted therapy. Furthermore, disease control status within a specific period of time is critical to the prediction of subsequent survival.
登录
查看更多内容
DOI：
10.1200/jco.2011.29.15_suppl.4560
发表时间：
2011-05
期刊：
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
影响因子：
--
作者：
D. Heng;W. Xie;L. Harshman;G. Bjarnason;U. Vaishampayan;J. Lebert;L. Wood;F. Donskov;M. Tan;S. Rha;C. Wells;Yulei N. Wang;C. Kollmannsberger;B. Rini;T. Choueiri
通讯作者：
D. Heng;W. Xie;L. Harshman;G. Bjarnason;U. Vaishampayan;J. Lebert;L. Wood;F. Donskov;M. Tan;S. Rha;C. Wells;Yulei N. Wang;C. Kollmannsberger;B. Rini;T. Choueiri
影响因子：
45.3
作者：
Janssen-Heijnen, Maryska L. G.;Gondos, Adam;Coebergh, Jan-Willem W.
通讯作者：
Coebergh, Jan-Willem W.
影响因子：
45.3
作者：
Motzer, RJ;Mazumdar, M;Ferrara, J
通讯作者：
Ferrara, J
DOI：
--
发表时间：
2013
期刊：
--
影响因子：
--
作者：
Jack Cuzick;I. Sestak;S. E. Pinder;Ian O. Ellis;Sharon Forsyth;N. Bundred;John F. Forbes;H. Bishop;Ian S. Fentiman;W. D. George
通讯作者：
Jack Cuzick;I. Sestak;S. E. Pinder;Ian O. Ellis;Sharon Forsyth;N. Bundred;John F. Forbes;H. Bishop;Ian S. Fentiman;W. D. George
DOI：
10.1002/ssu.2980100103
发表时间：
1994-01-01
期刊：
SEMINARS IN SURGICAL ONCOLOGY
影响因子：
--
作者：
HENSON, DE;RIES, LAG
通讯作者：
RIES, LAG